Compound drug composition for delivery and application of compound drug composition

A composition and drug technology, applied in the field of medicine, can solve the problems of short plasma half-life of oxytocin, short duration of uterine contraction effect, rise in body blood pressure, etc., and achieve small adverse reactions, strong activity, optimal onset time and duration Effect

Active Publication Date: 2014-12-10
WUHAN DOCAN PHARMA
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In order to overcome the shortcomings of oxytocin's short plasma half-life, short duration of uterine contraction, and blood pressure-increasing activity, and to overcome the relatively slow onset of ergot alka

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound drug composition for delivery and application of compound drug composition
  • Compound drug composition for delivery and application of compound drug composition
  • Compound drug composition for delivery and application of compound drug composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] experiment material

[0032] Test drug:

[0033] Oxytocin, white powder, content: 99.7%, batch number: 1311035, provided by Nanjing Jiqun Pharmaceutical Technology Co., Ltd., 1mg=547IU. Before use, weigh 36IU / 66μg, 12IU / 22μg, 4IU / 7μg oxytocin powder and dissolve them in 10ml normal saline respectively to obtain 3.6IU / ml, 1.2IU / ml, 0.4IU / ml oxytocin injection. Oxytocin injection needs to be prepared and used immediately, and the sample should be stored in the dark at 2-8°C.

[0034] Methergonovine maleate, content: 100.1%, batch number: 72621000213, provided by Nanjing Jiqun Pharmaceutical Technology Co., Ltd. Before use, weigh 3.6mg, 1.2mg, 0.4mg methysergide maleate powder and dissolve them in 10ml normal saline respectively to obtain 360μg / ml, 120μg / ml, 40μg / ml methysergide maleate injection . Methergometrine injection needs to be prepared and used immediately, and the sample should be stored in the dark at 2-8°C.

[0035]Compound methylergide injection, drug pr...

Embodiment 2

[0114] Example of prescription and preparation process of compound methylergometrine oxytocin injection:

[0115] The drug specifications are: methylergonovine maleate 0.5mg / mL, oxytocin 5I.U. / mL, 1mL / branch.

[0116]

[0117] Get 0.5 g of methylergonovine maleate, 5000 I.U. of oxytocin and 7 g of sodium chloride, add them to 800 ml of water for injection, stir until all are dissolved, and adjust the pH to 2.5 to 5. After adding activated carbon for adsorption, add water to make up to 1000ml, filter and sterilize with microporous membrane method, then quantitatively fill 1ml into an ampoule bottle to obtain the product. According to clinical needs, choose intramuscular or intravenous injection.

Embodiment 3

[0119] Compound methylergonovine maleate oxytocin injection prescription and preparation process example:

[0120] The drug specifications are: methylergonovine maleate 1mg / mL, oxytocin 5I.U. / mL, 1mL / branch.

[0121]

[0122] Take 1g of methylergonovine maleate, 5000I.U. of oxytocin and 7g of sodium chloride, add them to 800ml of water for injection, stir until they are completely dissolved, and adjust the pH to 2.5 to 5. After adding activated carbon for adsorption, add water to make up to 1000ml, filter and sterilize with microporous membrane method, then quantitatively fill 1ml into an ampoule bottle to obtain the product. According to clinical needs, choose intramuscular or intravenous injection.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a compound drug composition for delivery and an application of the compound drug composition. The compound drug composition for the delivery comprises the following active ingredients: oxytocin and methylergonovine, wherein methylergonovine is present in a form of free or pharmaceutically acceptable salt. The compound drug composition for the delivery can achieve purposes of attenuation and synergism; compared with the prior art, the compound drug composition has stronger activity, takes effect more quickly and has longer duration and smaller adverse reactions; and the composition can be prepared into the drug composition drug administered to mammals including human beings, and is used for treating massive haemorrhage caused by active intervention at the third stage of labor and after the delivery.

Description

technical field [0001] The invention relates to a compound pharmaceutical composition for childbirth and application thereof, belonging to the field of medicine. Background technique [0002] Oxytocin is the earliest peptide hormone synthesized by human beings. It is a disulfide bond-containing nonapeptide hormone secreted by the posterior lobe of the human pituitary gland. It is the most commonly used traditional uterine drug. Oxytocin is mainly used clinically for labor induction and antepartum uterine contraction. Weakness, postpartum hemorrhage, and incomplete uterine involution. It acts quickly and has a certain uterine contraction effect. After decades of clinical use, it is still the first-line drug for the prevention and treatment of postpartum hemorrhage. Oxytocin acts directly on the oxytocin receptors on the smooth muscle of the uterus, and mainly exerts uterine contraction on the uterine body before and after childbirth, and its strength of action is positively ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/11A61P15/04A61P7/04A61K31/437A61K38/095
Inventor 霍立茹余健杨建楠刘二军周静
Owner WUHAN DOCAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap